The drug manufacturers, Celgene Limited, have also announced a treatment continuation scheme whereby the NHS will cover the cost of Revlimid for the first 26 cycles of treatment, which typically last one month each, with further drug costs being met by the manufacturer.
Gareth Morgan, professor of haematology at the Royal Marsden NHS Foundation Trust, said that the decision was ‘a major step toward providing a critical new option for patients in the UK’.
Eric Low, chief executive of Myeloma UK, added: ‘It is now critically important that PCTs implement this guidance immediately and I urge them to do so.’
- Do you think PCTs will implement this guidance?
Comment below and tell us what you think